Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround
Built on substance, not hype, Teva's mega rally is just getting started.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
More in Finance & Markets
Thailand Eyes Pivot to Short-Term Debt as Bond Volatility Rises
Thailand may turn to shorter-term instruments to meet the government’s borrowing needs in the fiscal year starting Oct. 1, a top official said, as rising US Treasury yields drive turbulence across…
RBA delivered a risk management hike – TD Securities
TD Securities Macro Research’s Reserve Bank of Australia (RBA) note argues that the September 25bps hike to 4.60% was a risk-management move rather than the start of a new tightening cycle.
COCOBOD dismisses claims of international market exclusion, defends $1.4bn domestic financing shift
The Ghana Cocoa Board (COCOBOD) has dismissed claims that its decision to raise $1.4 billion from domestic investors to finance cocoa purchases for the 2026/2027 season is because it has been shut out of the international market.
COCOBOD dismisses claims of international market exclusion, defends $1.4bn domestic financing shift
The Ghana Cocoa Board (COCOBOD) has dismissed claims that its decision to raise $1.4 billion from domestic investors to finance cocoa purchases for the 2026/2027 season is because it has been shut out of the international market.
COCOBOD says $1.4bn domestic funding is a strategic shift, not market exclusion
The Ghana Cocoa Board (COCOBOD) has rejected suggestions that its decision to raise $1.4 billion from domestic investors to finance cocoa purchases for the 2026/2027 season is the result of being shut out of international financial markets.